Richard S Finn

Title(s)HS Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies. NPJ Breast Cancer. 2024 Jun 29; 10(1):54. Cheang MCU, Rimawi M, Johnston S, Jacobs SA, Bliss J, Pogue-Geile K, Kilburn L, Zhu Z, Schuster EF, Xiao H, Swaim L, Deng S, Lu DR, Gauthier E, Tursi J, Slamon DJ, Rugo HS, Finn RS, Liu Y. PMID: 38951507; PMCID: PMC11217366.
      View in: PubMed   Mentions:
    2. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist Updat. 2024 Jun 25; 76:101103. Glaviano A, Wander SA, Baird RD, Yap KC, Lam HY, Toi M, Carbone D, Geoerger B, Serra V, Jones RH, Ngeow J, Toska E, Stebbing J, Crasta K, Finn RS, Diana P, Vuina K, de Bruin RAM, Surana U, Bardia A, Kumar AP. PMID: 38943828.
      View in: PubMed   Mentions:    Fields:    
    3. Combination and Optimal Sequencing of Systemic and Locoregional Therapies in Hepatocellular Carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel. J Vasc Interv Radiol. 2024 Jun; 35(6):818-824. Thornton LM, Abi-Jaoudeh N, Lim HJ, Malagari K, Spieler BO, Kudo M, Finn RS, Lencioni R, White SB, Kokabi N, Jeyarajah DR, Chaudhury P, Liu D. PMID: 38789204.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights. JCO Oncol Pract. 2024 Apr 25; OP2400189. Rose MG, Kennedy EB, Abou-Alfa GK, Finn RS, Gade T, Kelley RK, Taddei T, Gordan JD. PMID: 38662970.
      View in: PubMed   Mentions:    Fields:    
    5. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. J Clin Oncol. 2024 Mar 19; JCO2302745. Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Kortmansky J, Leaf A, Remak WM, Sohal DPS, Taddei TH, Wilson Woods A, Yarchoan M, Rose MG. PMID: 38502889.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review. JAMA Oncol. 2024 Mar 01; 10(3):395-404. Cappuyns S, Corbett V, Yarchoan M, Finn RS, Llovet JM. PMID: 37535375; PMCID: PMC10837331.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    7. HIMALAYA Overall Survival Prominence and Other Routes to the Peak-Reply. JAMA Oncol. 2024 Mar 01; 10(3):1. Llovet JM, Cappuyns S, Finn RS. PMID: 38206615.
      View in: PubMed   Mentions:    Fields:    
    8. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024 Apr; 21(4):294-311. Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, Pikarsky E, Kudo M, Finn RS. PMID: 38424197.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    9. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat Med. 2024 Mar; 30(3):699-707. Kim HD, Jung S, Lim HY, Ryoo BY, Ryu MH, Chuah S, Chon HJ, Kang B, Hong JY, Lee HC, Moon DB, Kim KH, Kim TW, Tai D, Chew V, Lee JS, Finn RS, Koh JY, Yoo C. PMID: 38374347; PMCID: PMC10957471.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    10. Author Correction: Hepatocellular carcinoma. Nat Rev Dis Primers. 2024 Feb 12; 10(1):10. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. PMID: 38346997.
      View in: PubMed   Mentions:    Fields:    
    11. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. J Clin Oncol. 2024 Mar 20; 42(9):994-1000. Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS. PMID: 38252901; PMCID: PMC10950136.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    12. Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review. J Immunother Cancer. 2024 01 18; 12(1). Galle P, Finn RS, Mitchell CR, Ndirangu K, Ramji Z, Redhead GS, Pinato DJ. PMID: 38238030; PMCID: PMC10806538.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Single center experience using stereotactic body radiation therapy (SBRT) on orthotopic liver transplant protocol for unresectable cholangiocarcinoma. HPB (Oxford). 2024 Mar; 26(3):444-450. Wu TC, Deng J, Chu FI, Sadeghi S, Finn R, Agopian VG, Lee P, Raldow AC. PMID: 38142182.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Dec; 24(12):1399-1410. Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, LEAP-002 Investigators. PMID: 38039993.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    15. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023 Dec 01; 9(12):1651-1659. Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z, Satoh T, Marino D, Assenat E, Li S, Chen Y, Boisserie F, Abdrashitov R, Finn RS, Vogel A, Zhu AX. PMID: 37796513; PMCID: PMC10557031.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    16. The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results. Future Oncol. 2024 Jan; 20(1):5-16. Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. PMID: 37916267.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2- Metastatic Breast Cancer. Cancers (Basel). 2023 Sep 14; 15(18). Zhao JJ, Fong KY, Chan YH, Tey J, Dawood S, Lee SC, Finn RS, Sundar R, Lim JSJ. PMID: 37760527; PMCID: PMC10527344.
      View in: PubMed   Mentions: 1  
    18. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. EClinicalMedicine. 2023 Sep; 63:102179. Kulkarni AV, Tevethia H, Kumar K, Premkumar M, Muttaiah MD, Hiraoka A, Hatanaka T, Tada T, Kumada T, Kakizaki S, Vogel A, Finn RS, Rao PN, Pillai A, Reddy DN, Singal AG. PMID: 37680945; PMCID: PMC10480543.
      View in: PubMed   Mentions: 4  
    19. Evolution of Systemic Therapy in Advanced Hepatocellular Carcinoma. Surg Oncol Clin N Am. 2024 01; 33(1):73-85. Bejjani A, Finn RS. PMID: 37945146.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis. Liver Cancer. 2023 Dec; 12(6):510-520. Vogel A, Finn RS, Blanchet Zumofen MH, Heuser C, Alvarez JS, Leibfried M, Mitchell CR, Batson S, Redhead G, Gaillard VE, Kudo M. PMID: 38058419; PMCID: PMC10697759.
      View in: PubMed   Mentions:
    21. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 06 03; 401(10391):1853-1865. Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A, KEYNOTE-966 Investigators. PMID: 37075781.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansCTClinical Trials
    22. Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B. Clin Cancer Res. 2023 04 14; 29(8):1477-1483. Clark AS, Hong F, Finn RS, DeMichele AM, Mitchell EP, Zwiebel J, Arnaldez FI, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Copur MS, Kasbari SS, Thind R, Conley BA, Arteaga CL, O'Dwyer PJ, Harris LN, Chen AP, Flaherty KT. PMID: 36853016; PMCID: PMC10102836.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    23. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol. 2023 08; 20(8):487-503. Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenwälder M, El-Serag HB, Finn RS, Friedman SL. PMID: 36932227.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    24. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023 08; 79(2):506-515. Rimassa L, Finn RS, Sangro B. PMID: 36933770.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    25. Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study. Liver Cancer. 2023 Oct; 12(5):479-493. Kudo M, Finn RS, Cheng AL, Zhu AX, Ducreux M, Galle PR, Sakamoto N, Kato N, Nakano M, Jia J, Vogel A. PMID: 37901766; PMCID: PMC10601852.
      View in: PubMed   Mentions: 5  
    26. HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. Hepatology. 2023 03 01; 77(3):774-788. Sun N, Zhang C, Lee YT, Tran BV, Wang J, Kim H, Lee J, Zhang RY, Wang JJ, Hu J, Zhang Z, Alsudaney MS, Hou KC, Tang H, Zhang TX, Liang IY, Zhou Z, Chen M, Yeh AH, Li W, Zhou XJ, Chang HR, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Noureddin M, Ayoub WS, Kuo A, Sundaram V, Al-Ghaieb B, Palomique J, Kosari K, Kim IK, Todo T, Nissen NN, Tomasi ML, You S, Posadas EM, Wu JX, Wadehra M, Sim MS, Li Y, Wang HL, French SW, Lu SC, Wu L, Pei R, Liang L, Yang JD, Agopian VG, Tseng HR, Zhu Y. PMID: 35908246; PMCID: PMC9887095.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    27. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial. Liver Cancer. 2023 Sep; 12(4):309-320. Merle P, Kudo M, Edeline J, Bouattour M, Cheng AL, Chan SL, Yau T, Garrido M, Knox J, Daniele B, Breder V, Lim HY, Ogasawara S, Cattan S, Chao Y, Siegel AB, Martinez-Forero I, Wei Z, Liu CC, Finn RS. PMID: 37901200; PMCID: PMC10601873.
      View in: PubMed   Mentions: 6  
    28. Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. Clin Cancer Res. 2023 01 04; 29(1):40-49. Wainberg ZA, Singh AS, Konecny GE, McCann KE, Hecht JR, Goldman J, Chmielowski B, Finn RS, O'Brien N, Von Euw E, Price MM, Martinez D, Yonemoto L, Brennan M, Glaspy JA, Slamon DJ. PMID: 36136304.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    29. Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2. Oncologist. 2022 12 09; 27(12):e938-e948. Finn RS, Yau T, Hsu CH, De Toni EN, Goyal L, Galle PR, Qin S, Rao S, Sun F, Wang C, Widau RC, Zhu AX. PMID: 36190331; PMCID: PMC10249425.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    30. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study. Liver Cancer. 2023 Aug; 12(3):238-250. Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, Ikeda M, Tsuchiya K, Aoki KI, Jia J, Lencioni R. PMID: 37767068; PMCID: PMC10521324.
      View in: PubMed   Mentions: 7  
    31. Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3. Breast. 2022 Dec; 66:324-331. Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. PMID: 36463643; PMCID: PMC9720565.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    32. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ Breast Cancer. 2022 Oct 11; 8(1):114. Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A. PMID: 36220852; PMCID: PMC9553912.
      View in: PubMed   Mentions: 34  
    33. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. J Hepatol. 2023 01; 78(1):133-141. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Vogel A, Tovoli F, Ueshima K, Aikata H, López CL, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Tamai T, Saito K, Dutcus CE, Lencioni R. PMID: 36341767.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    34. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. Gastroenterology. 2023 01; 164(1):72-88.e18. Haber PK, Castet F, Torres-Martin M, Andreu-Oller C, Puigvehí M, Miho M, Radu P, Dufour JF, Verslype C, Zimpel C, Marquardt JU, Galle PR, Vogel A, Bathon M, Meyer T, Labgaa I, Digklia A, Roberts LR, Mohamed Ali MA, Mínguez B, Citterio D, Mazzaferro V, Finkelmeier F, Trojan J, Özdirik B, Müller T, Schmelzle M, Bejjani A, Sung MW, Schwartz ME, Finn RS, Thung S, Villanueva A, Sia D, Llovet JM. PMID: 36108710.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    35. Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab. Liver Cancer. 2023 Feb; 12(1):44-56. Hsu C, Ducreux M, Zhu AX, Qin S, Ikeda M, Kim TY, Galle PR, Finn RS, Chen E, Ma N, Hu Y, Li L, Cheng AL. PMID: 36872921; PMCID: PMC9982337.
      View in: PubMed   Mentions: 1  
    36. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. NPJ Precis Oncol. 2022 Aug 16; 6(1):56. Zhu Z, Turner NC, Loi S, André F, Martin M, Diéras V, Gelmon KA, Harbeck N, Zhang C, Cao JQ, Yan Z, Lu DR, Wei P, VanArsdale TL, Rejto PA, Huang X, Rugo HS, Loibl S, Cristofanilli M, Finn RS, Liu Y. PMID: 35974168; PMCID: PMC9381541.
      View in: PubMed   Mentions: 4  
    37. Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. Clin Cancer Res. 2022 08 15; 28(16):3443-3451. Kudo M, Montal R, Finn RS, Castet F, Ueshima K, Nishida N, Haber PK, Hu Y, Chiba Y, Schwartz M, Meyer T, Lencioni R, Llovet JM. PMID: 34907081.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    38. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022 08; 28(8):1599-1611. Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. PMID: 35739268.
      View in: PubMed   Mentions: 129     Fields:    Translation:Humans
    39. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clin Cancer Res. 2022 06 13; 28(12):2547-2554. Verset G, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer DH, Vogel A, Edeline J, Cattan S, Kudo M, Cheng AL, Ogasawara S, Daniele B, Chan SL, Knox JJ, Qin S, Siegel AB, Chisamore M, Hatogai K, Wang A, Finn RS, Zhu AX. PMID: 35421228.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    40. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res. 2022 Jun 02; 41(1):189. Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, Cattan S, Blanc JF, Lee KH, Maur M, Pant S, Kudo M, Assenat E, Zhu AX, Yau T, Lim HY, Bruix J, Geier A, Guillén-Ponce C, Fasolo A, Finn RS, Fan J, Vogel A, Qin S, Riester M, Katsanou V, Chaudhari M, Kakizume T, Gu Y, Porta DG, Myers A, Delord JP. PMID: 35655320; PMCID: PMC9161616.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    41. Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clin Cancer Res. 2022 06 01; 28(11):2297-2305. Llovet JM, Singal AG, Villanueva A, Finn RS, Kudo M, Galle PR, Ikeda M, Callies S, McGrath LM, Wang C, Abada P, Widau RC, Gonzalez-Gugel E, Zhu AX. PMID: 35247922; PMCID: PMC9662930.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    42. Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations. J Clin Oncol. 2022 08 20; 40(24):2763-2773. Bejjani AC, Finn RS. PMID: 35649192.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    43. Optimizing the Suboptimal: Hepatocellular Carcinoma Surveillance Guide for Primary Care Practitioners Based on a Medscape Education Online Activity. J Fam Pract. 2022 05; 71(4 Suppl):S2-S8. Finn R. PMID: 35728005.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    44. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer. 2022 05; 167:1-12. Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer DH, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Yau T, Gurary EB, Siegel AB, Wang A, Cheng AL, Zhu AX, KEYNOTE-224 Investigators. PMID: 35364421.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    45. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. Cardiovasc Intervent Radiol. 2022 Apr; 45(4):405-412. Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. PMID: 35119481; PMCID: PMC8940827.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    46. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022 01; 23(1):77-90. Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. PMID: 34914889.
      View in: PubMed   Mentions: 362     Fields:    Translation:HumansCTClinical Trials
    47. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022 Apr; 76(4):862-873. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS. PMID: 34902530.
      View in: PubMed   Mentions: 400     Fields:    Translation:Humans
    48. Circulating Tumor Cell-Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue-Based Messenger RNA Profiling Into a Noninvasive Setting. Liver Transpl. 2022 02; 28(2):200-214. Lee YT, Sun N, Kim M, Wang JJ, Tran BV, Zhang RY, Qi D, Zhang C, Chen PJ, Sadeghi S, Finn RS, Saab S, Han SB, Busuttil RW, Pei R, Zhu Y, Tseng HR, You S, Yang JD, Agopian VG. PMID: 34664394; PMCID: PMC8820407.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    49. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022 03; 19(3):151-172. Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. PMID: 34764464.
      View in: PubMed   Mentions: 462     Fields:    Translation:Humans
    50. Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer. JCO Oncol Pract. 2022 05; 18(5):319-327. McAndrew NP, Finn RS. PMID: 34637323.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    51. ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. Ther Adv Med Oncol. 2021; 13:17588359211039928. Vogel A, Merle P, Verslype C, Finn RS, Zhu AX, Cheng AL, Chan SL, Yau T, Ryoo BY, Knox J, Daniele B, Qin S, Wei Z, Miteva Y, Malhotra U, Siegel AB, Kudo M. PMID: 34616489; PMCID: PMC8488519.
      View in: PubMed   Mentions: 4  
    52. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer. 2021 09; 9(9). Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. PMID: 34518290; PMCID: PMC8438858.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    53. Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver Int. 2021 11; 41(11):2759-2767. Galle PR, Kudo M, Llovet JM, Finn RS, Karwal M, Pezet D, Kim TY, Yang TS, Lonardi S, Tomasek J, Phelip JM, Touchefeu Y, Koh SJ, Stirnimann G, Liang K, Ogburn KD, Wang C, Abada P, Widau RC, Zhu AX. PMID: 34173317.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    54. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer. 2021 Sep; 10(5):451-460. Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. PMID: 34721507; PMCID: PMC8527922.
      View in: PubMed   Mentions: 5  
    55. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study. Clin Cancer Res. 2021 09 01; 27(17):4848-4858. Finn RS, Kudo M, Cheng AL, Wyrwicz L, Ngan RKC, Blanc JF, Baron AD, Vogel A, Ikeda M, Piscaglia F, Han KH, Qin S, Minoshima Y, Kanekiyo M, Ren M, Dairiki R, Tamai T, Dutcus CE, Ikezawa H, Funahashi Y, Evans TRJ. PMID: 34108184; PMCID: PMC9401497.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    56. Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3. Oncologist. 2021 07; 26(7):e1143-e1155. Iwata H, Umeyama Y, Liu Y, Zhang Z, Schnell P, Mori Y, Fletcher O, Marshall JC, Johnson JG, Wood LS, Toi M, Finn RS, Turner NC, Bartlett CH, Cristofanilli M. PMID: 33955129; PMCID: PMC8265363.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    57. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 07; 22(7):991-1001. Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, Kudo M, Breder V, Merle P, Kaseb A, Li D, Mulla S, Verret W, Xu DZ, Hernandez S, Ding B, Liu J, Huang C, Lim HY, Cheng AL, Ducreux M. PMID: 34051880.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansCTClinical Trials
    58. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. J Gastroenterol. 2021 06; 56(6):570-580. Okusaka T, Ikeda K, Kudo M, Finn R, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrwicz L, Yoon JH, Ren Z, Mody K, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H. PMID: 33948712; PMCID: PMC8137475.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    59. Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α-fetoprotein: Outcomes by treatment-emergent ascites. Hepatol Res. 2021 Jun; 51(6):715-721. Kudo M, Ikeda M, Galle PR, Yamashita T, Finn RS, Liang K, Wang C, Sakaguchi S, Abada P, Widau RC, Zhu AX. PMID: 33743189.
      View in: PubMed   Mentions: 3  
    60. Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. Adv Mater Technol. 2021 May; 6(5). Sun N, Lee YT, Kim M, Wang JJ, Zhang C, Teng PC, Qi D, Zhang RY, Tran BV, Lee YT, Ye J, Palomique J, Nissen NN, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Posadas EM, Liang L, Pei R, Yang JD, You S, Agopian VG, Tseng HR, Zhu Y. PMID: 34212072; PMCID: PMC8240468.
      View in: PubMed   Mentions: 2  
    61. Functional Rhinoplasty and Uvuloplasty for Sleep-Disordered Breathing: A Step-by-Step Guide. J Oral Maxillofac Surg. 2021 04; 79(4):e7-e17. AbdelBaky O, Brothers J, Finn R. PMID: 33795070.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    62. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 2021 03 24; 23(1):37. DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS. PMID: 33761995; PMCID: PMC7989035.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    63. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. Oncologist. 2021 05; 26(5):e749-e755. Finn RS, Rugo HS, Gelmon KA, Cristofanilli M, Colleoni M, Loi S, Schnell P, Lu DR, Theall KP, Mori A, Gauthier E, Bananis E, Turner NC, Diéras V. PMID: 33486783; PMCID: PMC8100571.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    64. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021 04; 124(8):1388-1397. Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M. PMID: 33531690; PMCID: PMC8039038.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCellsCTClinical Trials
    65. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021 01 21; 7(1):6. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. PMID: 33479224.
      View in: PubMed   Mentions: 1965     Fields:    Translation:Humans
    66. Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib. Target Oncol. 2021 01; 16(1):69-76. Zheng J, Yu Y, Durairaj C, Diéras V, Finn RS, Wang DD. PMID: 33211314; PMCID: PMC7810610.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    67. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int. 2021 03; 41(3):598-607. Reig M, Galle PR, Kudo M, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX. PMID: 33188713; PMCID: PMC7898500.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    68. Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. Cancer. 2021 03 15; 127(6):865-874. Ryoo BY, Merle P, Kulkarni AS, Cheng AL, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist JM, Chen E, Siegel AB, Zhu AX, Finn RS, Kudo M. PMID: 33231873.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    69. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Rep. 2021 Apr; 3(2):100215. Kudo M, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, Llovet JM, Assenat E, Merle P, Chan SL, Palmer DH, Ikeda M, Yamashita T, Vogel A, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AX. PMID: 33392490; PMCID: PMC7772786.
      View in: PubMed   Mentions: 20  
    70. Evolution of Systemic Therapy for Hepatocellular Carcinoma. Hepatology. 2021 01; 73 Suppl 1:150-157. Finn RS, Zhu AX. PMID: 32380571.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    71. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol. 2020 10; 26(Suppl 1):S1-S40. Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. PMID: 33078723; PMCID: PMC7768980.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    72. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology. 2021 01; 73 Suppl 1:158-191. Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR, AASLD Panel of Experts on Trial Design in HCC. PMID: 32430997.
      View in: PubMed   Mentions: 161     Fields:    Translation:Humans
    73. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. Nat Commun. 2020 09 07; 11(1):4489. Sun N, Lee YT, Zhang RY, Kao R, Teng PC, Yang Y, Yang P, Wang JJ, Smalley M, Chen PJ, Kim M, Chou SJ, Bao L, Wang J, Zhang X, Qi D, Palomique J, Nissen N, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Markovic D, Elashoff D, Yu HH, Li H, Heaney AP, Posadas E, You S, Yang JD, Pei R, Agopian VG, Tseng HR, Zhu Y. PMID: 32895384; PMCID: PMC7477161.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    74. Management of ER positive metastatic breast cancer. Semin Oncol. 2020 Oct; 47(5):270-277. McAndrew NP, Finn RS. PMID: 32958261.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    75. Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply. N Engl J Med. 2020 08 13; 383(7):695. Finn RS, Cheng AL. PMID: 32786201.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    76. Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Res Treat. 2020 Nov; 184(1):23-35. Finn RS, Cristofanilli M, Ettl J, Gelmon KA, Colleoni M, Giorgetti C, Gauthier E, Liu Y, Lu DR, Zhang Z, Bartlett CH, Slamon DJ, Turner NC, Rugo HS. PMID: 32783178; PMCID: PMC7568717.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    77. Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors. Hepatol Commun. 2020 Oct; 4(10):1527-1540. Winograd P, Hou S, Court CM, Lee YT, Chen PJ, Zhu Y, Sadeghi S, Finn RS, Teng PC, Wang JJ, Zhang Z, Liu H, Busuttil RW, Tomlinson JS, Tseng HR, Agopian VG. PMID: 33024921; PMCID: PMC7527695.
      View in: PubMed   Mentions: 48     Fields:    
    78. Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO Open. 2020 08; 5(4). Zhu AX, Nipp RD, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Girvan A, Gable J, Bowman L, Wang C, Hsu Y, Abada PB, Kudo M. PMID: 32817068; PMCID: PMC7437873.
      View in: PubMed   Mentions: 8  Translation:Humans
    79. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020 09 10; 38(26):2960-2970. Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. PMID: 32716739; PMCID: PMC7479760.
      View in: PubMed   Mentions: 539     Fields:    Translation:HumansCTClinical Trials
    80. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020 12; 73(6):1460-1469. Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, Tang HT, Shen Y, Tschaika M, Neely J, El-Khoueiry A. PMID: 32710922; PMCID: PMC7751218.
      View in: PubMed   Mentions: 168     Fields:    Translation:HumansCTClinical Trials
    81. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020 Sep; 183(2):419-428. Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, Shparyk YV, Thummala A, Voitko N, Bananis E, McRoy L, Wilner K, Huang X, Kim S, Slamon DJ, Ettl J. PMID: 32683565; PMCID: PMC7383036.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    82. Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells. NPJ Precis Oncol. 2020; 4:16. Court CM, Hou S, Liu L, Winograd P, DiPardo BJ, Liu SX, Chen PJ, Zhu Y, Smalley M, Zhang R, Sadeghi S, Finn RS, Kaldas FM, Busuttil RW, Zhou XJ, Tseng HR, Tomlinson JS, Graeber TG, Agopian VG. PMID: 32637655; PMCID: PMC7331695.
      View in: PubMed   Mentions: 8  
    83. Carbon Dioxide Laser Resurfacing for Rhinophyma: A Case Report and Discussion of the Literature. J Oral Maxillofac Surg. 2020 Dec; 78(12):2296.e1-2296.e7. Graves LL, Hoopman J, Finn R. PMID: 32640206.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    84. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 05 14; 382(20):1894-1905. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL, IMbrave150 Investigators. PMID: 32402160.
      View in: PubMed   Mentions: 2454     Fields:    Translation:HumansCTClinical Trials
    85. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int. 2020 08; 40(8):2008-2020. Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomášek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH, Drove Ubreva N, Widau RC, Shinozaki K, Yoshikawa R, Zhu AX. PMID: 32279446.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    86. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Res. 2020 03 12; 22(1):27. Ettl J, Im SA, Ro J, Masuda N, Colleoni M, Schnell P, Bananis E, Lu DR, Cristofanilli M, Rugo HS, Finn RS. PMID: 32164785; PMCID: PMC7068918.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    87. Molecular therapies for HCC: Looking outside the box. J Hepatol. 2020 02; 72(2):342-352. Faivre S, Rimassa L, Finn RS. PMID: 31954496.
      View in: PubMed   Mentions: 150     Fields:    Translation:Humans
    88. Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. Liver Cancer. 2020 Jan; 9(1):93-104. Alsina A, Kudo M, Vogel A, Cheng AL, Tak WY, Ryoo BY, Evans TRJ, López López C, Daniele B, Misir S, Ren M, Izumi N, Qin S, Finn RS. PMID: 32071913; PMCID: PMC7024884.
      View in: PubMed   Mentions: 39  
    89. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020 01 20; 38(3):193-202. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL, KEYNOTE-240 investigators. PMID: 31790344.
      View in: PubMed   Mentions: 796     Fields:    Translation:HumansCTClinical Trials
    90. Correction: Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Res. 2019 Nov 15; 79(22):5897. Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson L, Karasic T, Llovet J, Finn R, Groopman J, El-Serag H, Monga S, Wang XW, Karin M, Schwartz R, Tanabe K, Roberts L, Gunaratne P, Tsung A, Brown K, Lawrence T, Salem R, Singal A, Kim A, Rabiee A, Resar L, Meyer J, Hoshida Y, He AR, Ghoshal K, Ryan P, Jaffee E, Guha C, Mishra L, Coleman N, Ahmed M. PMID: 31772073.
      View in: PubMed   Mentions: 3     Fields:    
    91. Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. Br J Cancer. 2019 Oct; 121(7):625. Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW. PMID: 31363170; PMCID: PMC6889263.
      View in: PubMed   Mentions: 2     Fields:    
    92. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am. 2019 10; 28(4):695-715. Sadeghi S, Bejjani A, Finn RS. PMID: 31472914.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    93. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. Clin Cancer Res. 2020 01 01; 26(1):110-121. Finn RS, Liu Y, Zhu Z, Martin M, Rugo HS, Diéras V, Im SA, Gelmon KA, Harbeck N, Lu DR, Gauthier E, Huang Bartlett C, Slamon DJ. PMID: 31527167.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    94. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clin Breast Cancer. 2020 04; 20(2):e173-e180. Rugo HS, Finn RS, Gelmon K, Joy AA, Harbeck N, Castrellon A, Mukai H, Walshe JM, Mori A, Gauthier E, Lu DR, Bananis E, Martin M, Diéras V. PMID: 31836434.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    95. The Place of Novel Therapies in the American Association for the Study of Liver Diseases Guidelines for Hepatocellular Carcinoma. Clin Liver Dis (Hoboken). 2019 Aug; 14(2):51-55. Bejjani A, Finn RS. PMID: 31508220; PMCID: PMC6726383.
      View in: PubMed   Mentions: 3  
    96. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Res. 2019 09 01; 79(17):4326-4330. Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, Llovet JM, Finn RS, Groopman JD, El-Serag HB, Monga SP, Wang XW, Karin M, Schwartz RE, Tanabe KK, Roberts LR, Gunaratne PH, Tsung A, Brown KA, Lawrence TS, Salem R, Singal AG, Kim AK, Rabiee A, Resar L, Hoshida Y, He AR, Ghoshal K, Ryan PB, Jaffee EM, Guha C, Mishra L, Coleman CN, Ahmed MM. PMID: 31481419; PMCID: PMC8330805.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    97. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Breast J. 2020 03; 26(3):368-375. Gelmon KA, Cristofanilli M, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleckman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ. PMID: 31448513; PMCID: PMC7155112.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    98. Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. Br J Cancer. 2019 07; 121(3):218-221. Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW. PMID: 31249394; PMCID: PMC6738107.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    99. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist. 2019 12; 24(12):1514-1525. Diéras V, Harbeck N, Joy AA, Gelmon K, Ettl J, Verma S, Lu DR, Gauthier E, Schnell P, Mori A, Rugo HS, Finn RS. PMID: 31217344; PMCID: PMC6975938.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    100. Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. J Glob Oncol. 2019 05; 5:1-19. Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, Toi M. PMID: 31125276; PMCID: PMC6550032.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    101. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol. 2019 Jun; 15(16):1811-1822. Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla TM, Tomasello G, Boisserie F, Hou J, Li X, Song J, Zhu AX. PMID: 30969136.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCTClinical Trials
    102. Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein. Lancet Oncol. 2019 04; 20(4):e191. Zhu AX, Finn RS, Galle PR, Llovet JM, Kudo M. PMID: 30942178.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    103. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. J Natl Cancer Inst. 2019 04 01; 111(4):419-430. Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS. PMID: 30032196; PMCID: PMC6449170.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    104. Progression-free survival: Starting point or endpoint in advanced HCC trial design? J Hepatol. 2019 06; 70(6):1062-1064. Finn RS. PMID: 30943425.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    105. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. Gastroenterology. 2019 05; 156(6):1731-1741. Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, Bruix J. PMID: 30738047.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCells
    106. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 02; 20(2):282-296. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M, REACH-2 study investigators. PMID: 30665869.
      View in: PubMed   Mentions: 728     Fields:    Translation:HumansCTClinical Trials
    107. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019 Feb; 174(1):271-278. Lee KWC, Lord S, Finn RS, Lim E, Martin A, Loi S, Lynch J, Friedlander M, Lee CK. PMID: 30465154.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    108. The Role of Angiogenesis in Hepatocellular Carcinoma. Clin Cancer Res. 2019 02 01; 25(3):912-920. Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, Finn RS. PMID: 30274981.
      View in: PubMed   Mentions: 218     Fields:    Translation:Humans
    109. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018 10; 15(10):599-616. Llovet JM, Montal R, Sia D, Finn RS. PMID: 30061739.
      View in: PubMed   Mentions: 819     Fields:    Translation:Humans
    110. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018 08; 68(2):723-750. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. PMID: 29624699.
      View in: PubMed   Mentions: 1714     Fields:    Translation:Humans
    111. Searching for common ground in a global disease. Hepatobiliary Surg Nutr. 2018 Aug; 7(4):297-299. Finn RS. PMID: 30221159; PMCID: PMC6131265.
      View in: PubMed   Mentions:
    112. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018 09; 101:123-133. Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S. PMID: 30053671.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    113. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma. Liver Transpl. 2018 07; 24(7):946-960. Court CM, Hou S, Winograd P, Segel NH, Li QW, Zhu Y, Sadeghi S, Finn RS, Ganapathy E, Song M, French SW, Naini BV, Sho S, Kaldas FM, Busuttil RW, Tomlinson JS, Tseng HR, Agopian VG. PMID: 29624843; PMCID: PMC6097911.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    114. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 07; 19(7):940-952. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M, KEYNOTE-224 investigators. PMID: 29875066.
      View in: PubMed   Mentions: 1161     Fields:    Translation:HumansCTClinical Trials
    115. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018 Jul; 68:16-24. Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. PMID: 29783126.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    116. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018 08; 69(2):353-358. Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. PMID: 29704513.
      View in: PubMed   Mentions: 151     Fields:    Translation:HumansCTClinical Trials
    117. Multiple Cranial Neuropathies From Nivolumab in a Patient With Metastatic Hepatocellular Carcinoma. Mayo Clin Proc. 2018 04; 93(4):540-541. Siegel CH, Finn RS, Ho MG. PMID: 29622100.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 03 24; 391(10126):1163-1173. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. PMID: 29433850.
      View in: PubMed   Mentions: 2188     Fields:    Translation:HumansCTClinical Trials
    119. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs. 2018 03; 29(3):271-280. Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, Finn RS, Joy AA, Ettl J, Rugo HS, Zheng J, Wilner KD, Wang DD. PMID: 29360661; PMCID: PMC5821476.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    120. Negative phase 3 study of 90Y microspheres versus sorafenib in HCC. Lancet Oncol. 2018 02; 19(2):e69. Llovet JM, Finn RS. PMID: 29413470.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    121. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 01; 67(1):358-380. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. PMID: 28130846.
      View in: PubMed   Mentions: 1649     Fields:    Translation:Humans
    122. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis. Hepatology. 2018 01; 67(1):422-435. Finn RS, Zhu AX, Farah W, Almasri J, Zaiem F, Prokop LJ, Murad MH, Mohammed K. PMID: 28881497.
      View in: PubMed   Mentions: 113     Fields:    Translation:Humans
    123. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 01 20; 36(3):276-282. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. PMID: 29182496; PMCID: PMC6075847.
      View in: PubMed   Mentions: 274     Fields:    Translation:HumansCTClinical Trials
    124. Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions. Clin Cancer Res. 2018 01 01; 24(1):73-83. Tak WY, Lin SM, Wang Y, Zheng J, Vecchione A, Park SY, Chen MH, Wong S, Xu R, Peng CY, Chiou YY, Huang GT, Cai J, Abdullah BJJ, Lee JS, Lee JY, Choi JY, Gopez-Cervantes J, Sherman M, Finn RS, Omata M, O'Neal M, Makris L, Borys N, Poon R, Lencioni R. PMID: 29018051.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    125. Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection. Liver Transpl. 2017 09; 23(9):1123-1132. Court CM, Harlander-Locke MP, Markovic D, French SW, Naini BV, Lu DS, Raman SS, Kaldas FM, Zarrinpar A, Farmer DG, Finn RS, Sadeghi S, Tomlinson JS, Busuttil RW, Agopian VG. PMID: 28688158.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    126. Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature. Hepatology. 2017 10; 66(4):1344-1346. Ono A, Goossens N, Finn RS, Schmidt WN, Thung SN, Im GY, Hoshida Y, Precision Liver Cancer Prevention Consortium. PMID: 28390144; PMCID: PMC5605396.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    127. Review of Regorafenib for the Treatment of Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y). 2017 Aug; 13(8):492-495. Finn RS. PMID: 28867981; PMCID: PMC5572963.
      View in: PubMed   Mentions: 2  
    128. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. AJR Am J Roentgenol. 2017 Oct; 209(4):722-732. Gomes AS, Monteleone PA, Sayre JW, Finn RS, Sadeghi S, Tong MJ, Britten CD, Busuttil RW. PMID: 28705059.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    129. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis. Hepatology. 2017 06; 65(6):1979-1990. Lee MW, Raman SS, Asvadi NH, Siripongsakun S, Hicks RM, Chen J, Worakitsitisatorn A, McWilliams J, Tong MJ, Finn RS, Agopian VG, Busuttil RW, Lu DSK. PMID: 28170115.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    130. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. J Clin Pharmacol. 2017 09; 57(9):1159-1173. Sun W, O'Dwyer PJ, Finn RS, Ruiz-Garcia A, Shapiro GI, Schwartz GK, DeMichele A, Wang D. PMID: 28419480.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    131. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017 Feb 28; 116(5):575-583. Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A. PMID: 28152546; PMCID: PMC5344293.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    132. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 01 07; 389(10064):56-66. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G, RESORCE Investigators. PMID: 27932229.
      View in: PubMed   Mentions: 1610     Fields:    Translation:HumansCTClinical Trials
    133. Developing a treatment plan for hepatocellular carcinoma: the continuum of care. Clin Adv Hematol Oncol. 2016 Dec; 14 Suppl 12(12):9-11. Finn RS. PMID: 27930618.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    134. Novel second-line treatments for hepatocellular carcinoma: Discussion. Clin Adv Hematol Oncol. 2016 Dec; 14 Suppl 12(12):12-13. Frenette CT, Lencioni R, Finn RS. PMID: 27930619.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    135. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 11 17; 375(20):1925-1936. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. PMID: 27959613.
      View in: PubMed   Mentions: 1036     Fields:    Translation:HumansCTClinical Trials
    136. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. Adv Radiat Oncol. 2016 Oct-Dec; 1(4):237-243. Sandler KA, Veruttipong D, Agopian VG, Finn RS, Hong JC, Kaldas FM, Sadeghi S, Busuttil RW, Lee P. PMID: 28740893; PMCID: PMC5514222.
      View in: PubMed   Mentions: 23  
    137. The Role of Liver Biopsy in Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y). 2016 Oct; 12(10):628-630. Finn RS. PMID: 27917077; PMCID: PMC5114505.
      View in: PubMed   Mentions: 8  
    138. The role of liver biopsy in hepatocellular carcinoma. Clin Adv Hematol Oncol. 2016 Oct; 14(10):759-761. Finn RS. PMID: 27930626.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    139. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells. Cancer Res. 2016 10 01; 76(19):5822-5831. Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, Penichet ML, Jung ME, Gera J, Lichtenstein A. PMID: 27530328; PMCID: PMC5100807.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    140. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 2016 06 28; 18(1):67. Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, Pinter T, Boer K, Patel R, Randolph S, Kim ST, Huang X, Schnell P, Nadanaciva S, Bartlett CH, Slamon DJ. PMID: 27349747; PMCID: PMC4924326.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCTClinical Trials
    141. Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. Liver Cancer. 2016 Jul; 5(3):221-32. Zhang B, Finn RS. PMID: 27493897; PMCID: PMC4960351.
      View in: PubMed   Mentions: 17  
    142. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016 07; 13(7):417-30. O'Leary B, Finn RS, Turner NC. PMID: 27030077.
      View in: PubMed   Mentions: 473     Fields:    Translation:Humans
    143. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016 Feb 09; 18(1):17. Finn RS, Aleshin A, Slamon DJ. PMID: 26857361; PMCID: PMC4746893.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansAnimals
    144. Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer. Oncotarget. 2015 Aug 28; 6(25):21685-703. Lin ML, Patel H, Remenyi J, Banerji CR, Lai CF, Periyasamy M, Lombardo Y, Busonero C, Ottaviani S, Passey A, Quinlan PR, Purdie CA, Jordan LB, Thompson AM, Finn RS, Rueda OM, Caldas C, Gil J, Coombes RC, Fuller-Pace FV, Teschendorff AE, Buluwela L, Ali S. PMID: 26280373; PMCID: PMC4673296.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    145. Treatment of Intermediate-Stage Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y). 2015 Aug; 11(8):545-7. Finn RS. PMID: 27118952; PMCID: PMC4843044.
      View in: PubMed   Mentions: 1  
    146. Treatment of intermediate-stage hepatocellular carcinoma. Clin Adv Hematol Oncol. 2015 Aug; 13(8):501-3. Finn RS. PMID: 26351811.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    147. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015 Aug; 12(8):436. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. PMID: 26099984.
      View in: PubMed   Mentions: 80     Fields:    
    148. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015 Jul; 12(7):408-24. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. PMID: 26054909.
      View in: PubMed   Mentions: 240     Fields:    Translation:Humans
    149. Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015 Jun; 14(3):234-5. Bodzin AS, Finn RS, Busuttil RW. PMID: 26063022.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    150. Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. Liver Cancer. 2015 Mar; 4(2):115-25. Siegel AB, El-Khoueiry AB, Finn RS, Guthrie KA, Goyal A, Venook AP, Blanke CD, Verna EC, Dove L, Emond J, Kato T, Samstein B, Busuttil R, Remotti H, Coffey A, Brown RS. PMID: 26020033; PMCID: PMC4439789.
      View in: PubMed   Mentions: 9  
    151. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Res Treat. 2015 Feb; 149(3):669-80. Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, Slamon DJ. PMID: 25663547.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    152. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015 Apr; 220(4):416-27. Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. PMID: 25690672.
      View in: PubMed   Mentions: 96     Fields:    Translation:Humans
    153. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan; 16(1):25-35. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. PMID: 25524798.
      View in: PubMed   Mentions: 818     Fields:    Translation:HumansCTClinical Trials
    154. DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. Genes Cancer. 2014 Nov; 5(11-12):407-19. Yang Y, Bardeleben C, Frost P, Hoang B, Shi Y, Finn R, Gera J, Lichtenstein A. PMID: 25568666; PMCID: PMC4279438.
      View in: PubMed   Mentions: 13  
    155. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014 Dec 01; 32(34):3840-7. O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP. PMID: 25349301.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansCTClinical Trials
    156. Course of the mandibular incisive canal and its impact on harvesting symphysis bone grafts. J Oral Maxillofac Surg. 2015 Feb; 73(2):258.e1-258.e12. Vu DD, Brockhoff HC, Yates DM, Finn R, Phillips C. PMID: 25579015.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    157. Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. Liver Cancer. 2014 Oct; 3(3-4):439-50. Raoul JL, Park JW, Kang YK, Finn RS, Kim JS, Yeo W, Polite BN, Chao Y, Walters I, Baudelet C, Lencioni R. PMID: 26280005; PMCID: PMC4531422.
      View in: PubMed   Mentions: 11  
    158. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology. 2014 Nov; 60(5):1697-707. Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, Wu C, Tanwandee T, Shao G, Walters IB, Dela Cruz C, Poulart V, Wang JH. PMID: 24996197.
      View in: PubMed   Mentions: 148     Fields:    Translation:HumansCTClinical Trials
    159. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol. 2014 Aug; 132(8):1005-9. McCannel TA, Chmielowski B, Finn RS, Goldman J, Ribas A, Wainberg ZA, McCannel CA. PMID: 24852144.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    160. Systemic therapy in HCC: lessons from brivanib. J Hepatol. 2014 Oct; 61(4):947-50. Bolos D, Finn RS. PMID: 24972045.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    161. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res. 2014 Jul 01; 20(13):3507-20. O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ. PMID: 24879796.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    162. Systemic therapy for cholangiocarcinoma. Clin Liver Dis (Hoboken). 2014 Apr; 3(4):86-89. Sadeghi S, Finn RS. PMID: 30992893; PMCID: PMC6448706.
      View in: PubMed   Mentions:
    163. Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. Hepat Oncol. 2014 Apr; 1(2):181-188. Rimassa L, Porta C, Borbath I, Daniele B, Finn RS, Raoul JL, Schwartz LH, He AR, Trojan J, Peck-Radosavljevic M, Abbadessa G, Goldberg T, Santoro A, Bruix J. PMID: 30190953; PMCID: PMC6095177.
      View in: PubMed   Mentions: 8  
    164. Hepatic Oncology: a journal for all stakeholders in liver cancer management. Hepat Oncol. 2014 Jan; 1(1):1. Finn RS, Bruix J. PMID: 30190933; PMCID: PMC6114006.
      View in: PubMed   Mentions:
    165. Survival after sorafenib: expect the unexpected. J Hepatol. 2014 Feb; 60(2):243-4. Finn RS. PMID: 24216446.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    166. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2014 Feb 01; 20(3):736-43. Finn RS, Press MF, Dering J, O'Rourke L, Florance A, Ellis C, Martin AM, Johnston S. PMID: 24198242.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    167. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Res Treat. 2013 Oct; 141(3):397-408. Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS. PMID: 24091768.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    168. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013 Dec 01; 19(23):6614-23. Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K. PMID: 24088738; PMCID: PMC4795808.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCTClinical Trials
    169. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013 Oct; 4(10):1592-605. Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A. PMID: 24009064; PMCID: PMC3858548.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansAnimalsCells
    170. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013 Oct 01; 31(28):3509-16. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. PMID: 23980090.
      View in: PubMed   Mentions: 269     Fields:    Translation:HumansCTClinical Trials
    171. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol. 2013 Dec; 59(6):1271-7. Finn RS, Poon RT, Yau T, Klümpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J. PMID: 23928403.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    172. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2013 Apr; 9(4 Suppl 2):1-24. Gish RG, Finn RS, Marrero JA. PMID: 24872793; PMCID: PMC4030702.
      View in: PubMed   Mentions: 6  
    173. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. Clin Adv Hematol Oncol. 2013 Apr; 11 Suppl 5:1-22; quiz 2 p following p22. Gish RG, Finn RS, Marrero JA. PMID: 23881427.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    174. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology. 2013 May; 57(5):1838-46. Finn RS, Aleshin A, Dering J, Yang P, Ginther C, Desai A, Zhao D, von Euw E, Busuttil RW, Slamon DJ. PMID: 23299860.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    175. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther. 2013 Jun; 12(6):890-900. Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Jensen MR, Quadt C, Liu M, Dubinett SM, Slamon DJ. PMID: 23493311; PMCID: PMC3681857.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    176. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):270-8. Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett SM, Slamon DJ. PMID: 23399957; PMCID: PMC3573351.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    177. Emerging targeted strategies in advanced hepatocellular carcinoma. Semin Liver Dis. 2013 Feb; 33 Suppl 1:S11-9. Finn RS. PMID: 23457035.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    178. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May; 12(5):632-42. Konecny GE, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Porta DG, Anderson L, Shi MM, Yovine A, Slamon DJ. PMID: 23443805.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    179. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther. 2013 Apr; 12(4):509-19. Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS. PMID: 23395886.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    180. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. PLoS One. 2013; 8(2):e56112. Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG. PMID: 23405260; PMCID: PMC3566064.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    181. Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer. Int J Mol Sci. 2013 Feb 01; 14(2):3094-109. Fejzo MS, Anderson L, von Euw EM, Kalous O, Avliyakulov NK, Haykinson MJ, Konecny GE, Finn RS, Slamon DJ. PMID: 23377018; PMCID: PMC3588033.
      View in: PubMed   Mentions: 27     Fields:    
    182. Expanding options for EGFR targeting in lung cancer. Transl Lung Cancer Res. 2012 Dec; 1(4):287-8. Chou T, Finn RS, Garon EB. PMID: 25806196; PMCID: PMC4367554.
      View in: PubMed   Mentions: 2  
    183. Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer. 2012 Nov; 1(3-4):247-56. Finn RS. PMID: 24159589; PMCID: PMC3760459.
      View in: PubMed   Mentions: 29  
    184. Rapidly quantifying drug sensitivity of dispersed and clumped breast cancer cells by mass profiling. Analyst. 2012 Dec 07; 137(23):5495-8. Chun J, Zangle TA, Kolarova T, Finn RS, Teitell MA, Reed J. PMID: 23057068; PMCID: PMC3494737.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    185. Brivanib: a review of development. Future Oncol. 2012 Sep; 8(9):1083-90. Chou T, Finn RS. PMID: 23030483.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    186. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther. 2012 Sep; 11(9):1978-87. Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS. PMID: 22761403.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    187. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev. 2013 May; 39(3):219-29. Hurvitz SA, Hu Y, O'Brien N, Finn RS. PMID: 22658319; PMCID: PMC3835685.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimals
    188. Relations between obstructive sleep apnea syndrome and specific cephalometric measurements, body mass index, and apnea-hypopnea index. J Oral Maxillofac Surg. 2012 Apr; 70(4):e278-83. Cillo JE, Thayer S, Dasheiff RM, Finn R. PMID: 22449433.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    189. Advanced HCC: emerging molecular therapies. Minerva Gastroenterol Dietol. 2012 Mar; 58(1):25-34. Finn RS. PMID: 22419002.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    190. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer. 2012 Jan 14; 12:16. Britten CD, Gomes AS, Wainberg ZA, Elashoff D, Amado R, Xin Y, Busuttil RW, Slamon DJ, Finn RS. PMID: 22244160; PMCID: PMC3292503.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    191. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012 Apr 01; 18(7):2090-8. Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, Baudelet C, Manekas D, Park JW. PMID: 22238246.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    192. Sorafenib use while waiting for liver transplant: we still need to wait. J Hepatol. 2012 Mar; 56(3):723-5. Finn RS. PMID: 22127280.
      View in: PubMed   Mentions:    Fields:    
    193. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011 Nov 01; 17(21):6905-13. Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ. PMID: 22028489.
      View in: PubMed   Mentions: 119     Fields:    Translation:Humans
    194. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg. 2011 Jun; 146(6):683-9. Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, Finn R, Durazo FA, Saab S, Tong MJ, Hiatt JR, Busuttil RW. PMID: 21690444.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    195. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma. J Am Coll Surg. 2011 Apr; 212(4):514-20; discussion 520-1. Hong JC, Petrowsky H, Kaldas FM, Farmer DG, Durazo FA, Finn RS, Saab S, Han SH, Lee P, Markovic D, Lassman C, Hiatt JR, Busuttil RW. PMID: 21463781.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    196. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell. 2011 Mar 08; 19(3):347-58. Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L, Zhao A, Busuttil RW, Yee H, Stein L, French DM, Finn RS, Lowe SW, Powers S. PMID: 21397858; PMCID: PMC3061399.
      View in: PubMed   Mentions: 195     Fields:    Translation:HumansAnimalsCells
    197. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2011 Apr 01; 17(7):1973-83. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris R, Baudelet C, Walters I, Raoul JL. PMID: 21349999.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    198. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res. 2011 Mar 15; 17(6):1591-602. Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC, Slamon DJ. PMID: 21278246; PMCID: PMC4598646.
      View in: PubMed   Mentions: 157     Fields:    Translation:HumansCells
    199. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. Exp Clin Transplant. 2010 Dec; 8(4):307-13. Saab S, McTigue M, Finn RS, Busuttil RW. PMID: 21143097.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    200. The anatomic basis of lingual nerve trauma associated with inferior alveolar block injections. J Oral Maxillofac Surg. 2010 Nov; 68(11):2833-6. Morris CD, Rasmussen J, Throckmorton GS, Finn R. PMID: 20832156.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    201. SRC: a century of science brought to the clinic. Neoplasia. 2010 Aug; 12(8):599-607. Aleshin A, Finn RS. PMID: 20689754; PMCID: PMC2915404.
      View in: PubMed   Mentions: 105     Fields:    Translation:HumansAnimals
    202. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther. 2010 Jul; 9(7):1985-94. Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ. PMID: 20587667; PMCID: PMC2939826.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    203. The geometry of skin flap rotation. J Oral Maxillofac Surg. 2010 Oct; 68(10):2545-8. Throckmorton GS, Williams FC, Potter JK, Finn R. PMID: 20452114.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    204. Drug therapy: sorafenib. Hepatology. 2010 May; 51(5):1843-9. Finn RS. PMID: 20432260.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    205. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 2010 Mar 15; 70(6):2264-73. Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor BS, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD. PMID: 20215513; PMCID: PMC3166660.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansCells
    206. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 2010 Mar 01; 16(5):1509-19. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS. PMID: 20179222.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansAnimalsCells
    207. Prolonged recovery associated with dexmedetomidine when used as a sole sedative agent in office-based oral and maxillofacial surgery procedures. J Oral Maxillofac Surg. 2010 Feb; 68(2):386-91. Makary L, Vornik V, Finn R, Lenkovsky F, McClelland AL, Thurmon J, Robertson B. PMID: 20116712.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    208. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res. 2010 Jan 15; 16(2):390-7. Finn RS. PMID: 20068087.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimals
    209. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol. 2009 Nov 20; 27(33):5552-8. Finn RS, Gagnon R, Di Leo A, Press MF, Arbushites M, Koehler M. PMID: 19858400.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    210. Clinical foundation for efficient treatment of obstructive sleep apnea. J Oral Maxillofac Surg. 2009 Oct; 67(10):2171-82. Dasheiff RM, Finn R. PMID: 19761911.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    211. What's positive about 'triple-negative' breast cancer? Future Oncol. 2009 Sep; 5(7):1015-25. Hurvitz SA, Finn RS. PMID: 19792970.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    212. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol. 2009 Aug 20; 27(24):3908-15. Finn RS, Press MF, Dering J, Arbushites M, Koehler M, Oliva C, Williams LS, Di Leo A. PMID: 19620495; PMCID: PMC2799151.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    213. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther. 2009 Apr; 9(4):503-9. Finn RS, Zhu AX. PMID: 19374603.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    214. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clin Breast Cancer. 2009 Feb; 9(1):16-22. Britten CD, Finn RS, Bosserman LD, Wong SG, Press MF, Malik M, Lum BL, Slamon DJ. PMID: 19299235; PMCID: PMC6042515.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    215. Reconstruction of the shallow vestibule edentulous mandible with simultaneous split thickness skin graft vestibuloplasty and mandibular endosseous implants for implant-supported overdentures. J Oral Maxillofac Surg. 2009 Feb; 67(2):381-6. Cillo JE, Finn R. PMID: 19138614.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    216. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009; 11(5):R77. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. PMID: 19874578; PMCID: PMC2790859.
      View in: PubMed   Mentions: 653     Fields:    Translation:HumansCells
    217. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7861-70. Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y, Danenberg K, Martin AM, Williams L, Oliva C, Stein S, Gagnon R, Arbushites M, Koehler MT. PMID: 19047115.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    218. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008 Dec 01; 26(34):5544-52. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF. PMID: 18955454; PMCID: PMC2651098.
      View in: PubMed   Mentions: 144     Fields:    Translation:HumansCTClinical Trials
    219. Targeting Src in breast cancer. Ann Oncol. 2008 Aug; 19(8):1379-1386. Finn RS. PMID: 18487549.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansAnimals
    220. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int. 2009 Feb; 29(2):284-90. Finn RS, Bentley G, Britten CD, Amado R, Busuttil RW. PMID: 18482274.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    221. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs. 2008 Jan; 19(1):77-84. Camidge DR, Gail Eckhardt S, Gore L, O'Bryant CL, Leong S, Basche M, Holden SN, Musib L, Baldwin J, Darstein C, Thornton D, Finn RS, Britten CD. PMID: 18043132.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    222. Using botox to treat a mohs defect repair complicated by a parotid fistula. J Oral Maxillofac Surg. 2007 Nov; 65(11):2357-60. Hatzis GP, Finn R. PMID: 17954340.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    223. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. Cancer Res. 2007 Oct 15; 67(20):9887-93. Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Ralston S, Rossi AM, Steyn SJ, Wagner L, Winter SM, Bhattacharya SK. PMID: 17942920.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    224. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007 Nov; 105(3):319-26. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. PMID: 17268817.
      View in: PubMed   Mentions: 157     Fields:    Translation:HumansCells
    225. Hemodynamic stability in medically treated hypothyroid patients undergoing intravenous sedation. J Oral Maxillofac Surg. 2007 Jan; 65(1):13-6. Cillo JE, Finn R. PMID: 17174757.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    226. Hemodynamics in elderly coronary artery disease patients undergoing propofol sedation. J Oral Maxillofac Surg. 2006 Sep; 64(9):1338-42. Cillo JE, Finn R. PMID: 16916666.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    227. TZ-transposition flap: an alternate method of lower lip reconstruction for partial thickness defects. J Oral Maxillofac Surg. 2006 Sep; 64(9):1381-4. Trokel Y, Finn R. PMID: 16916673.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    228. Combined open rhinoplasty with spreader grafts and laser-assisted uvuloplasty for sleep-disordered breathing: long-term subjective outcomes. J Oral Maxillofac Surg. 2006 Aug; 64(8):1241-7. Cillo JE, Finn R, Dasheiff RM. PMID: 16860217.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    229. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006 May 01; 12(9):2817-25. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS. PMID: 16675576.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCellsCTClinical Trials
    230. Correlation and comparison of body mass index on hemodynamics in hypertensive and normotensive patients undergoing intravenous sedation. J Oral Maxillofac Surg. 2006 Apr; 64(4):583-8. Cillo JE, Finn R. PMID: 16546636.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    231. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006 Feb 01; 66(3):1630-9. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. PMID: 16452222.
      View in: PubMed   Mentions: 348     Fields:    Translation:HumansAnimalsCells
    232. Moderate intravenous sedation for office-based full face laser resurfacing using a continuous infusion propofol pump. J Oral Maxillofac Surg. 2005 Jul; 63(7):903-7. Cillo JE, Finn R. PMID: 16003614.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    233. Hemodynamics and oxygen saturation during intravenous sedation for office-based laser-assisted uvuloplasty. J Oral Maxillofac Surg. 2005 Jun; 63(6):752-5. Cillo JE, Finn R. PMID: 15944969.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    234. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005 May; 41(5):1130-7. Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW. PMID: 15841454.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    235. EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. Cancer Biol Ther. 2004 Dec; 3(12):1243-9. Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC. PMID: 15611621.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    236. Hemophilic arthropathy. J Am Acad Orthop Surg. 2004 Jul-Aug; 12(4):234-45. Luck JV, Silva M, Rodriguez-Merchan EC, Ghalambor N, Zahiri CA, Finn RS. PMID: 15473675.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    237. Modified tumescent technique for outpatient facial laser resurfacing. J Oral Maxillofac Surg. 2004 Jul; 62(7):829-33. Potter JK, Finn R, Cillo J. PMID: 15218561.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    238. Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother Biol Response Modif. 2003; 21:223-33. Finn RS, Slamon DJ. PMID: 15338747.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    239. Analysis of donor risk in living-donor hepatectomy: the impact of resection type on clinical outcome. Am J Transplant. 2002 Sep; 2(8):780-8. Salamé E, Goldstein MJ, Kinkhabwala M, Kapur S, Finn R, Lobritto S, Brown R, Emond JC. PMID: 12243500.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    Richard's Networks
    Concepts (534)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (71)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-4-g3cb31450 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California